Login to get immediate access to this content.
LoginSpeaker: Shanu Modi, USA
#ESMO23: Breaking Science in Breast Cancer Video Series
Highlights on HER2-low unresectable and/or mBC: The DESTINY-Breast04 study
Abstract discussed:
- 376O - Trastuzumab deruxtecan (T-DXd) versus treatment of physician’s choice (TPC) in patients (pts) with HER2-low unresectable and/or metastatic breast cancer (mBC): Updated survival results of the randomized, phase 3 DESTINY-Breast04 study
Series objectives: To provide oncologists all over the world with succinct summaries of the most important study results on Breast Cancer, delivered by leading experts in video interviews.
Our selection gives a landscape view of the important scientific breakthroughs in the molecular classification, prognostication and prediction, state of art management and precision oncology in Breast Cancer.
The study results covered, and speakers in this video series, have been selected exclusively by ESMO.
Published on 24 Oct 2023
